Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens
18 Years
N/A
Female
Breast Cancer
Trial Information
Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens
In Argentina, Faslodex is indicated for treating postmenopausal women with hormone
receptor-positive locally advanced or metastatic breast cancer with recurrence during or
after adjuvant anti-oestrogen therapy or disease progression during anti-oestrogen
treatment. This study will provide information regarding the acceptability and compliance of
Argentina patients to Faslodex and will provide information regarding the efficacy of this
treatment in local population.
Inclusion Criteria:
- Postmenopausal women with hormone receptor-positive locally advanced or metastatic
breast cancer with recurrence during or after adjuvant anti-estrogen therapy or
disease progression during anti-estrogen treatment, currently receiving Faslodex
- Signature of the informed consent
Exclusion Criteria:
- Any contraindication to Faslodex administration
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To collect real life data of acceptability and compliance on the use of Faslodex in the Argentine population.
Outcome Time Frame:
monthly
Safety Issue:
No
Authority:
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Study ID:
NIS-OAR-FAS-2008/1
NCT ID:
NCT00878930
Start Date:
April 2009
Completion Date:
December 2010
Related Keywords:
- Breast Cancer
- Breast cancer
- Fulvestrant
- Faslodex
- Acceptability
- Compliance
- Efficacy
- Breast Neoplasms
Name | Location |
|---|
